{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:53:28Z","timestamp":1794304408275,"version":"4.9.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1053\/j.gastro.2021.07.042","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T11:28:59Z","timestamp":1627990139000},"page":"1118-1132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":872,"title":["Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management"],"prefix":"10.1053","volume":"161","author":[{"given":"Gerhard","family":"Rogler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.07.042_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11894-019-0698-1","article-title":"Extraintestinal manifestations of inflammatory bowel disease: epidemiology, etiopathogenesis, and management","volume":"21","author":"Garber","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1053\/j.gastro.2021.07.042_bib2","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0889-8553(01)00019-X","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"31","author":"Su","year":"2002","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1053\/j.gastro.2021.07.042_bib4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11894-003-0042-6","article-title":"Extraintestinal complications of inflammatory bowel disease","volume":"5","author":"Orchard","year":"2003","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1053\/j.gastro.2021.07.042_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejim.2019.04.015","article-title":"Clinical and patient reported outcomes of the multidisciplinary management in patients with inflammatory bowel disease-associated spondyloarthritis","volume":"64","author":"Luchetti","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1053\/j.gastro.2021.07.042_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pan.2020.02.007","article-title":"Idiopathic acute pancreatitis in patients with inflammatory bowel disease: a multicenter cohort study","volume":"20","author":"Garcia Garcia de Paredes","year":"2020","journal-title":"Pancreatology"},{"key":"10.1053\/j.gastro.2021.07.042_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ecco-jcc\/jjv153","article-title":"Inflammatory bowel disease and pancreatitis: a review","volume":"10","author":"Ramos","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00042737-200501000-00015","article-title":"Association of antibodies to exocrine pancreas with subtypes of Crohn's disease","volume":"17","author":"Klebl","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib11","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1097\/MIB.0000000000000429","article-title":"Chronological Order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tp.2019.01.06","article-title":"The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults","volume":"8","author":"Jang","year":"2019","journal-title":"Transl Pediatr"},{"key":"10.1053\/j.gastro.2021.07.042_bib13","first-page":"119","article-title":"Extraintestinal manifestations of chronic inflammatory bowel disease in children","volume":"28","author":"Grossman","year":"1970","journal-title":"Proc Inst Med Chic"},{"key":"10.1053\/j.gastro.2021.07.042_bib14","first-page":"22","article-title":"[Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease]","volume":"20","author":"Stawarski","year":"2006","journal-title":"Pol Merkur Lekarski"},{"key":"10.1053\/j.gastro.2021.07.042_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MPG.0000000000001455","article-title":"Extraintestinal manifestations of pediatric inflammatory bowel disease: prevalence, presentation, and anti-TNF treatment","volume":"65","author":"Greuter","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2021.07.042_bib16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MEG.0000000000001072","article-title":"Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications","volume":"30","author":"Herzog","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib17","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.3748\/wjg.v20.i23.7497","article-title":"Association between orofacial granulomatosis and Crohn's disease in children: systematic review","volume":"20","author":"Lazzerini","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000068900","article-title":"Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent","volume":"206","author":"Bogenrieder","year":"2003","journal-title":"Dermatology"},{"key":"10.1053\/j.gastro.2021.07.042_bib19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/00042737-200208000-00010","article-title":"Orofacial granulomatosis as initial manifestation of Crohn's disease: a report of two cases","volume":"14","author":"Girlich","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1651-2227.2005.tb01925.x","article-title":"Is orofacial granulomatosis in children a feature of Crohn's disease?","volume":"94","author":"Khouri","year":"2005","journal-title":"Acta Paediatr"},{"key":"10.1053\/j.gastro.2021.07.042_bib21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/gut.38.5.738","article-title":"Clinical patterns of familial inflammatory bowel disease","volume":"38","author":"Satsangi","year":"1996","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.042_bib22","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2009.199679","article-title":"New IBD genetics: common pathways with other diseases","volume":"60","author":"Lees","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.042_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5217\/ir.2019.00128","article-title":"Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases","volume":"18","author":"Kim","year":"2020","journal-title":"Intest Res"},{"key":"10.1053\/j.gastro.2021.07.042_bib24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/ard.2004.021774","article-title":"Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease","volume":"63","author":"Peeters","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.MIB.0000442011.60285.68","article-title":"Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients","volume":"20","author":"Weizman","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib26","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2011.02.046","article-title":"Recent insights into the genetics of inflammatory bowel disease","volume":"140","author":"Cho","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.042_bib27","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1053\/j.gastro.2020.02.023","article-title":"Prevalence and clinical features of inflammatory bowel diseases associated with monogenic variants, identified by whole-exome sequencing in 1000 children at a single center","volume":"158","author":"Crowley","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.042_bib28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MCG.0000000000000067","article-title":"Musculoskeletal manifestations in inflammatory bowel disease: a revisit in search of immunopathophysiological mechanisms","volume":"48","author":"Sheth","year":"2014","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib29","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2165\/11638120-000000000-00000","article-title":"Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease","volume":"72","author":"Trikudanathan","year":"2012","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2021.07.042_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12178-011-9085-8","article-title":"Inflammatory bowel disease associated arthropathy","volume":"4","author":"Arvikar","year":"2011","journal-title":"Curr Rev Musculoskelet Med"},{"key":"10.1053\/j.gastro.2021.07.042_bib31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1365-2036.1999.00630.x","article-title":"Effects of current and former cigarette smoking on the clinical course of Crohn's disease","volume":"13","author":"Cosnes","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.042_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00203-018-1506-2","article-title":"Smoking and the intestinal microbiome","volume":"200","author":"Savin","year":"2018","journal-title":"Arch Microbiol"},{"key":"10.1053\/j.gastro.2021.07.042_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059260","article-title":"Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans","volume":"8","author":"Biedermann","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2021.07.042_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ecco-jcc\/jjv238","article-title":"Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Severs","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.2008.096487","article-title":"Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies","volume":"69","author":"Sugiyama","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib36","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/00042737-200012080-00004","article-title":"Smoking and inflammatory bowel disease","volume":"12","author":"Rubin","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib37","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(95)91089-1","article-title":"HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies","volume":"345","author":"Scofield","year":"1995","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.07.042_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(02)07374-9","article-title":"Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease","volume":"359","author":"Grant","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.07.042_bib39","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","article-title":"MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)","volume":"33","author":"Grant","year":"2001","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.07.042_bib40","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/ibd\/izy318","article-title":"An increased abundance of Clostridiaceae characterizes arthritis in inflammatory bowel disease and rheumatoid arthritis: a cross-sectional study","volume":"25","author":"Muniz Pedrogo","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib41","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/annrheumdis-2016-211064","article-title":"Faecal microbiota study reveals specific dysbiosis in spondyloarthritis","volume":"76","author":"Breban","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/art.39802","article-title":"Brief report: dialister as a microbial marker of disease activity in spondyloarthritis","volume":"69","author":"Tito","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib43","first-page":"631","article-title":"The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis","volume":"11","author":"Karreman","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.042_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1155\/2013\/139702","article-title":"Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease","volume":"27","author":"Stolwijk","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib46","doi-asserted-by":"crossref","DOI":"10.5455\/apr.102920121510","article-title":"Enthesitis is an extraintestinal manifestation of pediatric inflammatory bowel disease","volume":"1","author":"Horton","year":"2012","journal-title":"Ann Paediatr Rheumatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib47","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/ibd.20942","article-title":"Musculoskeletal manifestations of inflammatory bowel disease","volume":"15","author":"Bourikas","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib48","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","article-title":"Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease","volume":"4","author":"Takeuchi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","article-title":"The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases","volume":"101","author":"El Miedany","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib51","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2005.041129","article-title":"Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib52","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib53","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3899\/jrheum.160952","article-title":"Antitumor necrosis factor-alpha therapy associated with inflammatory bowel disease: three cases and a systematic literature review","volume":"44","author":"Bieber","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib54","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review","volume":"15","author":"Guillo","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.07.042_bib56","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.042_bib57","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.07.042_bib58","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2021.07.042_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1053\/j.gastro.2021.07.042_bib60","article-title":"[Extraintestinal manifestations in Crohn's disease: risk factors and influence of intestinal surgery]","volume":"80","author":"Nascimbeni","year":"2009","journal-title":"Ann Ital Chir"},{"key":"10.1053\/j.gastro.2021.07.042_bib61","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ecco-jcc\/jjz095","article-title":"Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review","volume":"13","author":"Chateau","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MD.0b013e318187cc9c","article-title":"Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients","volume":"87","author":"Farhi","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.gastro.2021.07.042_bib63","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12016-017-8617-4","article-title":"Skin manifestations of inflammatory bowel disease","volume":"53","author":"Greuter","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1053\/j.gastro.2021.07.042_bib65","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s10620-019-05999-4","article-title":"Pyoderma gangrenosum in inflammatory bowel disease: a systematic review and meta-analysis","volume":"65","author":"States","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2021.07.042_bib66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000371879","article-title":"Severe Sweet's syndrome with elevated cutaneous interleukin-1beta after azathioprine exposure: case report and review of the literature","volume":"230","author":"Imhof","year":"2015","journal-title":"Dermatology"},{"key":"10.1053\/j.gastro.2021.07.042_bib67","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00042737-199707000-00013","article-title":"Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group","volume":"9","author":"Travis","year":"1997","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib68","first-page":"86","article-title":"Metastatic Crohn's disease","volume":"65","author":"Amarapurkar","year":"2017","journal-title":"J\u00a0Assoc Physicians India"},{"key":"10.1053\/j.gastro.2021.07.042_bib69","doi-asserted-by":"crossref","first-page":"8192150","DOI":"10.1155\/2017\/8192150","article-title":"Metastatic Crohn's disease: an approach to an uncommon but important cutaneous disorder","volume":"2017","author":"Aberumand","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1053\/j.gastro.2021.07.042_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.urology.2016.02.026","article-title":"Urogenital manifestations of metastatic Crohn's disease in children: case series and review of the literature","volume":"92","author":"Rani","year":"2016","journal-title":"Urology"},{"key":"10.1053\/j.gastro.2021.07.042_bib71","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/ibd.22904","article-title":"Development of metastatic Crohn's disease of the skin while on anti-TNF biologics","volume":"18","author":"Patel","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib72","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ibd.21082","article-title":"Adalimumab for cutaneous metastatic Crohn's disease","volume":"16","author":"Cury","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib73","article-title":"Oral manifestations of inflammatory bowel disease and the role of non-invasive surrogate markers of disease activity","volume":"7","author":"Ribaldone","year":"2020","journal-title":"Medicines (Basel)"},{"key":"10.1053\/j.gastro.2021.07.042_bib74","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.3748\/wjg.v22.i25.5655","article-title":"Oral pathology in inflammatory bowel disease","volume":"22","author":"Muhvic-Urek","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib75","article-title":"Prevalence of oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: a systematic review","volume":"9","author":"Lauritano","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.gastro.2021.07.042_bib76","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apt.13217","article-title":"Review article: non-malignant oral manifestations in inflammatory bowel diseases","volume":"42","author":"Katsanos","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.042_bib77","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1097\/01.MIB.0000438356.84263.3b","article-title":"Periodontitis and gingivitis in inflammatory bowel disease: a case-control study","volume":"19","author":"Vavricka","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MEG.0b013e32835a2b70","article-title":"Subgingival microflora in inflammatory bowel disease patients with untreated periodontitis","volume":"25","author":"Brito","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib79","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1600-051X.2008.01231.x","article-title":"Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis","volume":"35","author":"Brito","year":"2008","journal-title":"J\u00a0Clin Periodontol"},{"key":"10.1053\/j.gastro.2021.07.042_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.21663","article-title":"Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE","volume":"18","author":"Lofberg","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ecco-jcc\/jjv178","article-title":"Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits","volume":"10","author":"Taleban","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib82","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ecco-jcc\/jjy029","article-title":"Ocular manifestations of paediatric inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Ottaviano","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib83","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.3748\/wjg.v23.i32.5836","article-title":"Ophthalmic manifestations in patients with inflammatory bowel disease: a review","volume":"23","author":"Troncoso","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"60","author":"Watson","year":"1976","journal-title":"Br J Ophthalmol"},{"key":"10.1053\/j.gastro.2021.07.042_bib85","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MEG.0000000000000532","article-title":"Primary sclerosing cholangitis associated with inflammatory bowel disease: an update","volume":"28","author":"Rossi","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib86","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1572-0241.2007.01103.x","article-title":"The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis","volume":"102","author":"Kaplan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MEG.0000000000000747","article-title":"Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort study: prevalence, risk factors, and long-term follow-up","volume":"29","author":"Fraga","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31311","article-title":"The role of the intestine in the pathogenesis of primary sclerosing cholangitis: evidence and therapeutic implications","volume":"72","author":"Dean","year":"2020","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.07.042_bib89","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"Bergquist","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib90","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s10620-006-9681-4","article-title":"Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"52","author":"Fevery","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2021.07.042_bib91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib92","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1136\/gutjnl-2018-316801","article-title":"Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis","volume":"68","author":"Rupp","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.042_bib93","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.51.5.731","article-title":"Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis","volume":"51","author":"Bjornsson","year":"2002","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.042_bib94","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/2040622315605821","article-title":"A\u00a0review of the medical treatment of primary sclerosing cholangitis in the 21st century","volume":"7","author":"Goode","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib95","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib96","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"34","author":"Triantos","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.042_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003626.pub2","article-title":"Bile acids for primary sclerosing cholangitis","author":"Poropat","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2021.07.042_bib98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4292\/wjgpt.v4.i3.61","article-title":"Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy","volume":"4","author":"Treeprasertsuk","year":"2013","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.042_bib99","first-page":"16","article-title":"Recurrence of primary sclerosing cholangitis after liver transplantation\u2014The Hungarian experience","volume":"6","author":"Gelley","year":"2014","journal-title":"Interv Med Appl Sci"},{"key":"10.1053\/j.gastro.2021.07.042_bib100","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/j.transproceed.2012.07.098","article-title":"Activity of ulcerative colitis before and after liver transplantation in primary sclerosing cholangitis: the Hungarian experience","volume":"44","author":"Gelley","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1053\/j.gastro.2021.07.042_bib101","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hep.23035","article-title":"Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone","volume":"50","author":"Zeitz","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2021.07.042_bib102","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/ibd.21219","article-title":"Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease","volume":"16","author":"Navaneethan","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib103","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MPG.0000000000001492","article-title":"Hepatic issues and complications associated with inflammatory bowel disease: a clinical report from the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees","volume":"64","author":"Saubermann","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2021.07.042_bib104","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/liv.13265","article-title":"Hepatic manifestations of inflammatory bowel diseases","volume":"37","author":"Restellini","year":"2017","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2021.07.042_bib105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12794","article-title":"Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease","volume":"40","author":"Gizard","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.042_bib106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bpg.2009.10.011","article-title":"Gastrointestinal and liver adverse effects of drugs used for treating IBD","volume":"24","author":"Rogler","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib107","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/0003319720918509","article-title":"Aortic stiffening is an extraintestinal manifestation of inflammatory bowel disease: review of the literature and expert panel statement","volume":"71","author":"Zanoli","year":"2020","journal-title":"Angiology"},{"key":"10.1053\/j.gastro.2021.07.042_bib108","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/ibd\/izy354","article-title":"Risk of myocardial infarction in inflammatory bowel disease: a population-based national study","volume":"25","author":"Panhwar","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.07.042_bib109","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.cgh.2018.04.031","article-title":"Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases","volume":"16","author":"Aniwan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib110","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/acr.22892","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in cutaneous lupus erythematosus: a population-based cohort study","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.gastro.2021.07.042_bib111","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","article-title":"Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study","volume":"67","author":"Kirchgesner","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.042_bib112","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2020.06.005","article-title":"Venous thromboembolic events in inflammatory bowel diseases: a review of current evidence and guidance on risk in the post-hospitalization setting","volume":"194","author":"Murthy","year":"2020","journal-title":"Thromb Res"},{"key":"10.1053\/j.gastro.2021.07.042_bib113","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1572-0241.2006.00943.x","article-title":"Inflammation and coagulation in inflammatory bowel disease: the clot thickens","volume":"102","author":"Danese","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib114","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.thromres.2008.04.004","article-title":"Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis","volume":"123","author":"Shen","year":"2009","journal-title":"Thromb Res"},{"key":"10.1053\/j.gastro.2021.07.042_bib115","first-page":"136","article-title":"Crohn's disease and acute pancreatitis. A review of literature","volume":"16","author":"Jasdanwala","year":"2015","journal-title":"JOP"},{"key":"10.1053\/j.gastro.2021.07.042_bib116","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/MPG.0b013e3182065cad","article-title":"Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients","volume":"52","author":"Broide","year":"2011","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1053\/j.gastro.2021.07.042_bib117","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MCG.0b013e3181cadbe1","article-title":"Pancreatitis in inflammatory bowel diseases","volume":"44","author":"Pitchumoni","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib118","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4292\/wjgpt.v10.i2.35","article-title":"Crohn's disease of esophagus, stomach and duodenum","volume":"10","author":"Pimentel","year":"2019","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1053\/j.gastro.2021.07.042_bib119","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.2169\/internalmedicine.0213-17","article-title":"Type 2 autoimmune pancreatitis with crohn's disease","volume":"57","author":"Suk Lee","year":"2018","journal-title":"Intern Med"},{"key":"10.1053\/j.gastro.2021.07.042_bib120","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/gut.32.10.1192","article-title":"Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease","volume":"32","author":"Seibold","year":"1991","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2021.07.042_bib121","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00004836-199604000-00010","article-title":"Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies","volume":"22","author":"Seibold","year":"1996","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib122","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1572-0241.1999.01015.x","article-title":"Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease","volume":"94","author":"Heikius","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib123","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/ecco-jcc\/jjz165","article-title":"Interstitial and granulomatous lung disease in inflammatory bowel disease patients","volume":"14","author":"Eliadou","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"issue":"6","key":"10.1053\/j.gastro.2021.07.042_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156666","article-title":"Pain in IBD patients: very frequent and frequently insufficiently taken into account","volume":"11","author":"Zeitz","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2021.07.042_bib125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib126","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.3748\/wjg.v16.i25.3168","article-title":"Impact of pain on health-related quality of life in patients with inflammatory bowel disease","volume":"16","author":"Schirbel","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib127","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ecco-jcc\/jjz148","article-title":"Longitudinal trajectory of fatigue with initiation of biologic therapy in inflammatory bowel diseases: a prospective cohort study","volume":"14","author":"Borren","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.07.042_bib128","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MOG.0000000000000644","article-title":"Fatigue in inflammatory bowel disease: a problematic ailment","volume":"36","author":"Qazi","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1053\/j.gastro.2021.07.042_bib129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11894-020-0746-x","article-title":"Sleep and fatigue in IBD: an unrecognized but important extra-intestinal manifestation","volume":"22","author":"Canakis","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1053\/j.gastro.2021.07.042_bib130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41575-018-0091-9","article-title":"Fatigue in IBD: epidemiology, pathophysiology and management","volume":"16","author":"Borren","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib131","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12325-019-01151-w","article-title":"Fatigue in inflammatory bowel diseases: etiologies and management","volume":"37","author":"Nocerino","year":"2020","journal-title":"Adv Ther"},{"key":"10.1053\/j.gastro.2021.07.042_bib132","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5114\/reum.2015.53998","article-title":"Fatigue and interleukin-6\u2014a multi-faceted relationship","volume":"53","author":"Grygiel-Gorniak","year":"2015","journal-title":"Reumatologia"},{"key":"10.1053\/j.gastro.2021.07.042_bib133","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cgh.2020.03.013","article-title":"Alterations in fecal microbiomes and serum metabolomes of fatigued patients with quiescent inflammatory bowel diseases","volume":"19","author":"Borren","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2021.07.042_bib134","article-title":"Interventions for fatigue in inflammatory bowel disease","volume":"4","author":"Farrell","year":"2020","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521033370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521033370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:49:59Z","timestamp":1762163399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521033370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0016508521033370"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.07.042","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute","name":"copyright","label":"Copyright"}]}}